Research
Bifidobacterium breve
38 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Restoration of gut microbiota with a specific synbiotic-containing infant formula in healthy Chinese infants born by cesarean section.
RCT investigating the effect of a synbiotic mixture containing Bifidobacterium breve and scGOS/lcFOS on gut microbiota development in C-section and vaginally-born infants. The synbiotic enhanced bifidobacterial species diversity and restored gut colonizers in C-section born infants, with effects observed beyond the intervention period.
The Probiotics in Pediatric Asthma Management (PROPAM) Study in the Primary Care Setting: A Randomized, Controlled, Double-Blind Trial with Ligilactobacillus salivarius LS01 (DSM 22775) and Bifidobacterium breve B632 (DSM 24706)
The PROPAM study was a randomized, placebo-controlled, double-blind trial involving 422 children to assess the effect of a probiotic mixture containing Ligilactobacillus salivarius LS01 and Bifidobacterium breve B632 on asthma exacerbations. The probiotic significantly reduced the number of asthmatic exacerbations, demonstrating safety and efficacy as an auxiliary remedy in pediatric asthma management.
Fermented infant formula (with Bifidobacterium breve C50 and Streptococcus thermophilus O65) with prebiotic oligosaccharides is safe and modulates the gut microbiota towards a microbiota closer to that of breastfed infants.
RCT investigating the effect of a fermented infant formula containing Bifidobacterium breve, Streptococcus thermophilus, and prebiotics on gut microbiota and SIgA levels in infants. The formula improved SIgA levels and microbiota composition towards that of breastfed infants, indicating positive effects on gut health and immunity.
A randomised controlled trial of the probiotic Bifidobacterium breve BBG-001 in preterm babies to prevent sepsis, necrotising enterocolitis and death: the Probiotics in Preterm infantS (PiPS) trial.
This double-blind, randomised, placebo-controlled trial tested the probiotic Bifidobacterium breve BBG-001 in preterm babies to prevent necrotising enterocolitis, late-onset sepsis, and death. The study included 1310 babies and found no evidence of benefit for the primary outcomes, with similar rates of sepsis, NEC, and death between the probiotic and placebo groups.
The impact of Bifidobacterium breve BBr60 (BBr60) on metabolic and gastrointestinal health in healthy adults: A combined in vitro metabolomic and randomized, double-blind, placebo-controlled study.
This study evaluated the effects of Bifidobacterium breve BBr60 on metabolic and gastrointestinal health in 109 healthy adults over 8 weeks. The BBr60 group showed significant improvements in HDL levels, reductions in total cholesterol, and enhanced gastrointestinal health. Neuropsychiatric symptoms related to alcohol consumption were alleviated, and emotional states improved, with increased positive emotional scores and decreased negative scores.
Ability of Bifidobacterium breve 702258 to transfer from mother to infant: the MicrobeMom randomized controlled trial.
This double-blinded, placebo-controlled RCT investigated if maternal supplementation of Bifidobacterium breve 702258 from early pregnancy until 3 months postpartum could transfer to the infant gut. The presence of the supplemented strain was detected in 2 infants in the intervention group and none in the control group, indicating infrequent direct mother-to-infant strain transfer.
Effect of Probiotic Bifidobacterium breve in Improving Cognitive Function and Preventing Brain Atrophy in Older Patients with Suspected Mild Cognitive Impairment: Results of a 24-Week Randomized, Double-Blind, Placebo-Controlled Trial.
RCT of 130 older patients with suspected mild cognitive impairment comparing Bifidobacterium breve MCC1274 to placebo for 24 weeks. Cognitive function improved on some subscales, and probiotic supplementation tended to suppress brain atrophy progression, particularly in subjects with progressed brain atrophy.
Supplementation with Bifidobacterium breve BR03 and B632 strains improved insulin sensitivity in children and adolescents with obesity in a cross-over, randomized double-blind placebo-controlled trial.
Cross-over, double-blind, randomized control trial assessing the impact of Bifidobacterium breve BR03 and B632 supplementation on insulin sensitivity in 101 youths with obesity. Probiotics improved insulin sensitivity at fasting and during OGTT, with no adverse events reported.
Bifidobacterium breve BBG-001 and intestinal barrier function in preterm babies: Exploratory Studies from the PiPS Trial.
RCT of Bifidobacterium breve BBG-001 in 94 preterm babies assessing intestinal permeability, stool microbiota, SCFAs, and mucosal inflammation. The trial found no evidence of efficacy in reducing necrotising enterocolitis or modifying intestinal barrier function.
Probiotic Bifidobacterium breve in Improving Cognitive Functions of Older Adults with Suspected Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial.
RCT of 80 healthy older adults with suspected MCI testing Bifidobacterium breve A1 (MCC1274) versus placebo for 16 weeks. The probiotic group showed significant improvements in cognitive functions, particularly in immediate memory, visuospatial/constructional, and delayed memory, with no adverse events reported.
Efficacy of Bifidobacterium breve and Lactobacillus casei oral supplementation on necrotizing enterocolitis in very-low-birth-weight preterm infants: a double-blind, randomized, controlled trial.
A double-blind, randomized, controlled trial in 231 very-low-birth-weight preterm infants assessed the efficacy of Bifidobacterium breve and Lactobacillus casei supplementation in preventing necrotizing enterocolitis (NEC). The intervention group showed a reduction in NEC occurrence compared to the control group, suggesting improved intestinal motility contributed to the positive outcome.
Effects of long-term consumption of a fermented infant formula (with Bifidobacterium breve c50 and Streptococcus thermophilus 065) on acute diarrhea in healthy infants.
RCT of 971 infants aged 4 to 6 months comparing fermented infant formula with Bifidobacterium breve C50 and Streptococcus thermophilus 065 to standard formula over 5 months. The fermented formula reduced the severity of acute diarrhea, with fewer cases of dehydration, medical consultations, ORS prescriptions, and formula switches.
Bifidobacterium breve Bif195 ameliorates aspirin-induced gastric mucosal damage: A randomised, double blind, placebo-controlled crossover trial.
A randomised, double-blind, placebo-controlled crossover trial with 25 healthy volunteers evaluated the effect of Bifidobacterium breve Bif195 on aspirin-induced gastric mucosal damage. Bif195 significantly reduced gastric Lanza scores compared to placebo, indicating a protective effect against aspirin-induced gastric damage.
Bifidobacterium breve CCFM1025 attenuates major depression disorder via regulating gut microbiome and tryptophan metabolism: A randomized clinical trial.
RCT assessing Bifidobacterium breve CCFM1025 in 45 patients with major depression disorder. The probiotic showed a better antidepressant-like effect than placebo, improving mood and gastrointestinal symptoms. Mechanisms may involve changes in gut microbiome and tryptophan metabolism.
Bifidobacteriumbreve Bif195 Protects Against Small-Intestinal Damage Caused by Acetylsalicylic Acid in Healthy Volunteers.
RCT of 75 healthy volunteers assessing the efficacy of Bifidobacterium breve (Bif195) in reducing small-intestinal damage caused by acetylsalicylic acid (ASA). The Bif195 group showed significantly lower AUC for intestinal damage and ulcer number compared to placebo, indicating a protective effect against ASA-induced enteropathy.
Synbiotics modulate gut microbiota and reduce enteritis and ventilator-associated pneumonia in patients with sepsis: a randomized controlled trial.
RCT of 72 sepsis patients in ICU comparing synbiotics to no synbiotics. Synbiotics group had significantly lower incidence of enteritis and ventilator-associated pneumonia. Fecal Bifidobacterium and Lactobacillus counts and organic acid concentrations were higher in the synbiotics group.
A synbiotic-containing amino-acid-based formula improves gut microbiota in non-IgE-mediated allergic infants.
This multicenter, double-blind, randomized controlled trial investigated the effects of an amino-acid-based formula including a synbiotic blend on gut microbiota in infants with suspected non-IgE-mediated cow's milk allergy. The test formula, containing fructo-oligosaccharides and Bifidobacterium breve M-16V, improved bifidobacteria levels and reduced ER/CC levels compared to the control formula without synbiotics.
The Association of Bifidobacterium breve BR03 and B632 is Effective to Prevent Colics in Bottle-fed Infants: A Pilot, Controlled, Randomized, and Double-Blind Study.
Pilot RCT assessing the effectiveness of Bifidobacterium breve BR03 and B632 in reducing crying in bottle-fed infants with colics. No significant differences were found overall, but during the third month, the probiotic group cried significantly less than the placebo group.
Intestinal Microbiota in Pediatric Surgical Cases Administered Bifidobacterium Breve: A Randomized Controlled Trial.
RCT examining the effects of orally administered Bifidobacterium breve strain Yakult (BBG-01) on pediatric surgical cases. BBG-01 was well tolerated and significantly decreased postoperative infectious complications. Fecal analysis showed increased Bifidobacterium and decreased harmful bacteria, with improved intestinal environment and reduced bacterial translocation.
Effect of Bifidobacterium breve M-16V supplementation on fecal bifidobacteria in preterm neonates--a randomised double blind placebo controlled trial.
RCT assessing Bifidobacterium breve M-16V supplementation in preterm neonates. The probiotic group showed a significant increase in fecal B. breve counts compared to placebo, with no adverse effects or deaths. B. breve M-16V is deemed suitable for routine use in this population.
A fermented formula in pre-term infants: clinical tolerance, gut microbiota, down-regulation of faecal calprotectin and up-regulation of faecal secretory IgA.
RCT evaluating a fermented pre-term infant formula containing Bifidobacterium breve and Streptococcus thermophilus. The formula was well tolerated, reduced faecal calprotectin, and increased secretory IgA, indicating benefits on inflammatory and immune markers.
A non-hydrolyzed, fermented milk formula reduces digestive and respiratory events in infants at high risk of allergy.
This multicenter, randomized, double-blind, controlled study evaluated the impact of a non-hydrolyzed fermented infant formula containing heat-killed Bifidobacterium breve and Streptococcus thermophilus on allergy-like events in infants at high risk of atopy. The formula reduced the incidence of digestive and respiratory potentially allergic adverse events compared to standard infant formula.
Effect of a new synbiotic mixture on atopic dermatitis in infants: a randomized-controlled trial.
RCT of 90 infants with atopic dermatitis comparing a synbiotic mixture containing Bifidobacterium breve and a galacto-/fructooligosaccharide mixture to placebo. No overall improvement in AD severity was observed, but the synbiotic group showed significant modulation of intestinal microbiota. In infants with IgE-associated AD, the synbiotic group showed greater improvement in SCORAD score.
Perioperative synbiotic treatment to prevent infectious complications in patients after elective living donor liver transplantation: a prospective randomized study.
Prospective randomized study of 50 adult patients undergoing elective living-donor liver transplantation. Patients received perioperative synbiotic therapy with Bifidobacterium breve, Lactobacillus casei, and galactooligosaccharides. The BLO group had significantly fewer infectious complications compared to the control group.
Effect of a fermented formula on thymus size and stool pH in healthy term infants.
RCT investigating the effects of fermented formula with Bifidobacterium breve C50 and Streptococcus thermophilus 065 on thymus size and stool pH in 90 healthy term infants. The fecal pH of the FF group was similar to the breast-fed group and lower than the standard formula group. The FF infants showed a thymus index similar to breast-fed newborns, suggesting probiotic fermentation products may support immune responses.
Effects of bifidobacterium breve supplementation on intestinal flora of low birth weight infants.
Controlled trial studying the effects of Bifidobacterium breve supplementation on low birth weight infants. Early administration of B. breve promoted the colonization of Bifidobacterium and formation of normal intestinal flora, with group A showing earlier colonization and lower Enterobacteriaceae levels compared to group B and the control group.
Clinical intervention using Bifidobacterium strains in celiac disease children reveals novel microbial modulators of TNF-α and short-chain fatty acids.
Double-blind placebo-controlled study of 40 children with celiac disease and 16 healthy children, examining the effects of Bifidobacterium breve strains on gut microbiota, TNF-α, and short-chain fatty acids. Probiotic administration showed correlations with microbiome changes and potential anti-inflammatory effects.
Effect of Synbiotic on the Gut Microbiota of Cesarean Delivered Infants: A Randomized, Double-blind, Multicenter Study.
RCT assessing the effect of synbiotic supplementation with scGOS, lcFOS, and Bifidobacterium breve M-16V on the gut microbiota of cesarean-born infants. Synbiotic supplementation increased bifidobacteria proportion and reduced Enterobacteriaceae, with lower fecal pH and higher acetate, supporting early modulation of gut microbiota similar to vaginally delivered infants.
Effect of Bifidobacterium breve on the Intestinal Microbiota of Coeliac Children on a Gluten Free Diet: A Pilot Study.
Pilot study evaluating the effect of Bifidobacterium breve supplementation on the intestinal microbiota of coeliac children on a gluten-free diet. The probiotic administration for three months increased Bifidobacterium levels and helped restore the healthy microbial balance.
Administration of Bifidobacterium breve Decreases the Production of TNF-α in Children with Celiac Disease.
Double-blinded, placebo-controlled trial of Bifidobacterium breve strains BR03 and B632 in 49 children with celiac disease on a gluten-free diet. The probiotic intervention significantly decreased TNF-α levels, indicating a positive effect on inflammation.
Capability of the two microorganisms Bifidobacterium breve B632 and Bifidobacterium breve BR03 to colonize the intestinal microbiota of children.
RCT assessing the capability of Bifidobacterium breve B632 and Bifidobacterium breve BR03 to colonize the intestinal microbiota of children. After 21 days of supplementation, there was a significant increase in total fecal bifidobacteria and a decrease in total coliforms, suggesting effective gut colonization and potential use in colicky infants.
Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study.
RCT of 41 patients with mild to moderate ulcerative colitis comparing synbiotic treatment with Bifidobacterium breve strain Yakult and galacto-oligosaccharide to control. The synbiotic group showed significant improvement in clinical status, reduced myeloperoxidase levels, and decreased fecal Bacteroidaceae counts and pH.
Effects of the enteral administration of Bifidobacterium breve on patients undergoing chemotherapy for pediatric malignancies.
A placebo-controlled trial at Juntendo University Hospital evaluated the effects of enteral administration of Bifidobacterium breve strain Yakult on infection prevention and intestinal environments in 42 pediatric cancer patients undergoing chemotherapy. The probiotic group showed lower frequency of fever, reduced use of intravenous antibiotics, and better maintenance of intestinal microbiota and organic acid levels compared to the placebo group.
Bifidobacterium breve enhances transforming growth factor beta1 signaling by regulating Smad7 expression in preterm infants.
RCT examining the effect of Bifidobacterium breve supplementation on TGF-beta signaling in 19 preterm infants. B. breve group showed elevated serum TGF-beta1 levels and altered Smad expression, suggesting potential benefits in reducing inflammatory and allergic reactions.
Early administration of Bifidobacterium breve to preterm infants: randomised controlled trial.
RCT investigating the colonisation of Bifidobacterium breve in very low birthweight infants. The study found that early administration of B breve significantly decreased aspirated air volume from the stomach and improved weight gain, suggesting effective colonisation and positive effects on gut health and nutrition.
Oral administration of Bifidobacterium breve promotes antitumor efficacy via dendritic cells-derived interleukin 12
The study investigates the antitumor efficacy of oral administration of Bifidobacterium breve in an animal model. It found that B. breve significantly inhibited tumor growth and up-regulated tumor cell apoptosis through the recruitment of tumor-infiltrating lymphocytes and dendritic cells, enhancing interleukin 12 secretion.
[Trial of oral administration of Bifidobacterium breve for the prevention of rotavirus infections].
RCT evaluating the effect of Bifidobacterium breve YIT4064 on preventing rotavirus infection in infants. The B. breve group showed significantly lower rotavirus shedding and increased anti-IgA in stool samples compared to the control group.
Synbiotics decrease the incidence of septic complications in patients with severe SIRS: a preliminary report.
Observational study of 29 SIRS patients receiving synbiotics compared to 26 patients without. Synbiotics improved gut flora and reduced the incidence of infectious complications such as enteritis, pneumonia, and bacteremia.